Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

For patients with HFPEF and other underlying comorbidities ... as defined by prespecified clinical and echocardiographic criteria, and hospitalized for a cardiovascular cause within the previous ...

This Safety Guide presents a coherent set of generic criteria (expressed numerically in terms of radiation dose) that form a basis for developing the operational levels needed for decision making ...

Further editorial criteria may be applicable for different kinds of papers, as follows: Articles published in Nature have an exceptionally wide impact, both among scientists and, frequently ...

Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.

USA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin ...

The trial was done in adults with obesity and heart failure with preserved ejection fraction (HFpEF). The data, posted online on August 1, has not yet been published in a peer-reviewed journal.